治疗年龄相关性黄斑变性时玻璃体内注射雷珠单抗的视觉预后与延迟之间的关系

RELATIONSHIP BETWEEN VISUAL PROGNOSIS AND DELAY OF INTRAVITREAL INJECTION OF RANIBIZUMAB WHEN TREATING AGE-RELATED MACULAR DEGENERATION.

作者信息

Takahashi Hidenori, Ohkubo Yuko, Sato Aya, Takezawa Mikiko, Fujino Yujiro, Yanagi Yasuo, Kawashima Hidetoshi

机构信息

*Jichi Medical University, Shimotsuke-shi, Japan; †Department of Ophthalmology, Japan Community Health Care Organization Tokyo Shinjuku Medical Center, Tokyo, Japan; and ‡Department of Ophthalmology, The University of Tokyo, Tokyo, Japan.

出版信息

Retina. 2015 Jul;35(7):1331-8. doi: 10.1097/IAE.0000000000000513.

DOI:10.1097/IAE.0000000000000513

PMID:25719984

Abstract

BACKGROUND

In age-related macular degeneration, various factors in clinical practice cause delays to arise between the time exudative change is observed and the time anti-vascular endothelial growth factor drugs are actually injected. We investigated the influence of injection delay on prognosis.

METHODS

Subjects were 50 eyes (50 patients from 2 hospitals) that were administered ranibizumab monotherapy for age-related macular degeneration for 1 year since exudative change was first observed. We investigated the mean number of delay days for each injection.

RESULTS

Mean injection delay was between 0 and 104 days. Significant prognostic factors for visual acuity were initial best-corrected visual acuity (P < 0.01) and mean injection delay (P = 0.03). We estimated that for an initial best-corrected visual acuity of 0.40 logMAR unit (20/50 Snellen equivalent), the respective best-corrected visual acuity values after 1 year for mean injection delays of 0, 7, 14, 28, and 56 days would be 0.22 (20/33), 0.24 (20/35), 0.26 (20/37), 0.31 (20/40), and 0.39 (20/49). For an initial best-corrected visual acuity of 0.097 (20/25), the respective values would be 0.054 (20/23), 0.075 (20/24), 0.10 (20/25), 0.14 (20/28), and 0.22 (20/33).

CONCLUSION

Long-term visual acuity prognosis worsened when scheduling problems delayed intravitreal injection of anti-vascular endothelial growth factor drugs.

摘要

背景

在年龄相关性黄斑变性中，临床实践中的各种因素导致在观察到渗出性改变与实际注射抗血管内皮生长因子药物之间出现延迟。我们研究了注射延迟对预后的影响。

方法

研究对象为50只眼（来自2家医院的50例患者），自首次观察到渗出性改变起，接受雷珠单抗单药治疗年龄相关性黄斑变性1年。我们调查了每次注射的平均延迟天数。

结果

平均注射延迟在0至104天之间。视力的显著预后因素为初始最佳矫正视力（P < 0.01）和平均注射延迟（P = 0.03）。我们估计，对于初始最佳矫正视力为0.40 logMAR单位（20/50 Snellen等效值），平均注射延迟分别为0、7、14、28和56天时，1年后各自的最佳矫正视力值将分别为0.22（20/33）、0.24（20/35）、0.26（20/37）、0.31（20/40）和0.39（20/49）。对于初始最佳矫正视力为0.097（20/25），各自的值将分别为0.054（20/23）、0.075（20/24）、0.10（20/25）、0.14（20/28）和0.22（20/33）。